Cargando…
Ocular Barriers and Their Influence on Gene Therapy Products Delivery
The eye is formed by tissues and cavities that contain liquids whose compositions are highly regulated to ensure their optical properties and their immune and metabolic functions. The integrity of the ocular barriers, composed of different elements that work in a coordinated fashion, is essential to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143174/ https://www.ncbi.nlm.nih.gov/pubmed/35631584 http://dx.doi.org/10.3390/pharmaceutics14050998 |
_version_ | 1784715740676358144 |
---|---|
author | Leclercq, Bastien Mejlachowicz, Dan Behar-Cohen, Francine |
author_facet | Leclercq, Bastien Mejlachowicz, Dan Behar-Cohen, Francine |
author_sort | Leclercq, Bastien |
collection | PubMed |
description | The eye is formed by tissues and cavities that contain liquids whose compositions are highly regulated to ensure their optical properties and their immune and metabolic functions. The integrity of the ocular barriers, composed of different elements that work in a coordinated fashion, is essential to maintain the ocular homeostasis. Specialized junctions between the cells of different tissues have specific features which guarantee sealing properties and selectively control the passage of drugs from the circulation or the outside into the tissues and within the different ocular compartments. Tissues structure also constitute selective obstacles and pathways for various molecules. Specific transporters control the passage of water, ions, and macromolecules, whilst efflux pumps reject and eliminate toxins, metabolites, or drugs. Ocular barriers, thus, limit the bioavailability of gene therapy products in ocular tissues and cells depending on the route chosen for their administration. On the other hand, ocular barriers allow a real local treatment, with limited systemic side-effects. Understanding the different barriers that limit the accessibility of different types of gene therapy products to the different target cells is a prerequisite for the development of efficient gene delivery systems. This review summarizes actual knowledge on the different ocular barriers that limit the penetration and distribution of gene therapy products using different routes of administration, and it provides a general overview of various methods used to bypass the ocular barriers. |
format | Online Article Text |
id | pubmed-9143174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91431742022-05-29 Ocular Barriers and Their Influence on Gene Therapy Products Delivery Leclercq, Bastien Mejlachowicz, Dan Behar-Cohen, Francine Pharmaceutics Review The eye is formed by tissues and cavities that contain liquids whose compositions are highly regulated to ensure their optical properties and their immune and metabolic functions. The integrity of the ocular barriers, composed of different elements that work in a coordinated fashion, is essential to maintain the ocular homeostasis. Specialized junctions between the cells of different tissues have specific features which guarantee sealing properties and selectively control the passage of drugs from the circulation or the outside into the tissues and within the different ocular compartments. Tissues structure also constitute selective obstacles and pathways for various molecules. Specific transporters control the passage of water, ions, and macromolecules, whilst efflux pumps reject and eliminate toxins, metabolites, or drugs. Ocular barriers, thus, limit the bioavailability of gene therapy products in ocular tissues and cells depending on the route chosen for their administration. On the other hand, ocular barriers allow a real local treatment, with limited systemic side-effects. Understanding the different barriers that limit the accessibility of different types of gene therapy products to the different target cells is a prerequisite for the development of efficient gene delivery systems. This review summarizes actual knowledge on the different ocular barriers that limit the penetration and distribution of gene therapy products using different routes of administration, and it provides a general overview of various methods used to bypass the ocular barriers. MDPI 2022-05-06 /pmc/articles/PMC9143174/ /pubmed/35631584 http://dx.doi.org/10.3390/pharmaceutics14050998 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Leclercq, Bastien Mejlachowicz, Dan Behar-Cohen, Francine Ocular Barriers and Their Influence on Gene Therapy Products Delivery |
title | Ocular Barriers and Their Influence on Gene Therapy Products Delivery |
title_full | Ocular Barriers and Their Influence on Gene Therapy Products Delivery |
title_fullStr | Ocular Barriers and Their Influence on Gene Therapy Products Delivery |
title_full_unstemmed | Ocular Barriers and Their Influence on Gene Therapy Products Delivery |
title_short | Ocular Barriers and Their Influence on Gene Therapy Products Delivery |
title_sort | ocular barriers and their influence on gene therapy products delivery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143174/ https://www.ncbi.nlm.nih.gov/pubmed/35631584 http://dx.doi.org/10.3390/pharmaceutics14050998 |
work_keys_str_mv | AT leclercqbastien ocularbarriersandtheirinfluenceongenetherapyproductsdelivery AT mejlachowiczdan ocularbarriersandtheirinfluenceongenetherapyproductsdelivery AT beharcohenfrancine ocularbarriersandtheirinfluenceongenetherapyproductsdelivery |